LifeMD acquires allergy telehealth platform Cleared; total consideration up to $76.7M

LifeMD, Inc.

Upfront $460k cash + $3.46M milestone payments + up to $72.8M earn-out based on $150M revenue.
Acquisition expected to close in Q1 2022; Cleared provides allergy/asthma telehealth in all 50 states.
Deal expected to be accretive to LifeMD's Adjusted EBITDA in 2022 and significantly accretive thereafter.
LifeMD also purchasing a $507k convertible note from a strategic pharma investor alongside the acquisition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.